Over 1‐year duration and age difference of SARS‐CoV‐2 antibodies in convalescent COVID‐19 patients. Issue 12 (26th July 2021)

• Record Type: Journal Article
• Authors: Zeng, Fanfan; Wu, Mengjun; Wang, Jinbiao; Li, Jianyu; Hu, Guoyun; Wang, Lin
• Other Names: Luo Guangxiang (George) guestEditor.; Ly Hinh guestEditor.; Gao Shou‐Jiang guestEditor.
• Is Part Of: Journal of medical virology. Volume 93:Issue 12(2021)
• Page Start: 6506
• Page End: 6511
• Publication Date: 2021-07-26
• Subjects: age difference of SARS‐CoV‐2 antibody response -- COVID‐19 convalescent patients -- SARS‐CoV‐2 antibody duration; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.27152
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: Anti‐severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) immunoglouilin G (IgG) and immunoglouilin M (IgM) antibodies have been widely used to assist clinical diagnosis. Our previous study reported a discrepancy in SARS‐CoV‐2 antibody response between male and female coronavirus disease 2019 (COVID‐19) patients. However, the duration and discrepancy between ages as well as sexes of SARS‐CoV‐2 antibody in convalescent COVID‐19 patients have not been clarified. In this study, a total of 538 health‐examination individuals who were confirmed with SARS‐CoV‐2 infection a year ago were enrolled. Blood samples were collected and detected for IgM and IgG antibodies. Among these convalescent patients, 12.80% were detected positive for IgM antibodies. The positive rates for IgM antibody were close between sexes: for males, this is 9.17% and for females 13.75%. However, the IgG antibody was detected positive in as much as 82.90% convalescent patients and the positive rates were nearly the same between males (82.57%) and females (82.98%). Besides this, the level of IgM and IgG antibodies showed no difference between male and female convalescent patients. The level of IgG antibodies showed a significant difference between ages. The elder patients (over 35 years old) maintained a higher level of IgG antibody than the younger patients (under or equal 35 years old) after recovering for 1 year. In addition, IgG antibody was more vulnerable to disappear in younger patients than in elder patients. Overall, our study identified over 1‐year duration of SARS‐CoV‐2 antibody and age difference of IgG antibody response in convalescent COVID‐19 patients. These findings may provide new insights into long‐term humoral immune response, vaccines efficacy and age‐based personalized vaccination strategies. Highlights: Anti‐SARS‐CoV‐2 IgG antibody could maintain over 1‐year in most convalescent COVID‐19 patients. Anti‐SARS‐CoV‐2 IgG antibody responses may be different between young and elder convalescent COVID‐19 patients.